RxDoctor Payments Data

Abram Mozes, MD

Clinical Cardiac Electrophysiology · Smithtown, NYNPI 1568418689

Payments from drug & device makers

$10,330in general payments, 2019–2025

Across 379 payments — averaging $27.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Medical Device Business Services, Inc.$885
  • Johnson & Johnson$713
  • Novartis$586
  • E.r. Squibb & Sons, L.L.C.$584
  • Pfizer$518
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$2,02020%
  • Food & beverage$8,30980%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,330 in reported general payments places this provider in the 30th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$483,884
Medicare patients
1,425
Services billed
3,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$62,144
EntrestoSacubitril/Valsartan14$19,308
FarxigaDapagliflozin Propanediol14$13,402
Diltiazem 24hr Er (Cd)Diltiazem Hcl33$2,008
Metoprolol Succinate47$971
Amiodarone Hcl27$550
Carvedilol28$264
Losartan Potassium26$237
Flecainide Acetate13$215
Furosemide25$194
Amlodipine Besylate21$98
Hydrochlorothiazide16$94
Atorvastatin Calcium12$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$518$62,14442 claims
NovartisEntresto$586$19,30814 claims
AstraZenecaFarxiga$155$13,40214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Smithtown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →